News & Events
Published On: 3/1/2021
Andrew von Eschenbach, M.D. Joins Target RWE as Senior Advisor
Former FDA Commissioner to Provide Strategic Counsel to Support Company's Rapid Expansion as Leading Real-World Evidence Platform
DURHAM, N.C., March 1, 2021 /PRNewswire/ -- Target RWE, a leading real-world evidence (RWE) solutions company for the pharmaceutical and biotech industries, today announced that Dr. Andrew von Eschenbach has joined the Company as a Senior Advisor. In this role, Dr. von Eschenbach will help guide and support the Company's continued growth and expansion.
Neal Bibeau, Chief Executive Officer of Target RWE, said, "It's an honor and tremendous opportunity to have another globally recognized leader in medicine like Andy von Eschenbach join Target RWE as a Senior Advisor. His extensive professional background – as a clinical and research oncologist, Director of the National Cancer Institute and FDA Commissioner, among other distinctions – will benefit us greatly as we continue to advance our position as a critical partner to the worldwide healthcare community. Andy deeply appreciates the potential of real-world data and evidence for the research and care of a broad range of diseases. We're eager to continue expanding Target's innovative RWE platform with the benefit of his insight and experience."
Dr. von Eschenbach will work alongside Dr. Franz Humer, former CEO and Chairman of Roche Holding Ltd. and a Senior Advisor to Target RWE, to help the Company build strategic relationships and continue developing its innovative RWE platform, in addition to guiding the Company on emerging market developments.
Dr. von Eschenbach commented, "This is an exciting time to join Target RWE as the Company gains significant momentum in the complex and rapidly growing real-world evidence space. High-quality, longitudinal, real-world data and evidence have never been more promising than right now. Target's innovative health evidence platform, developed by some of the sharpest minds in the business, is well positioned to lead the healthcare industry in purpose-built real-world data solutions. I'm looking forward to collaborating with Neal, Franz Humer, and the rest of the team to help realize Target's full potential in their contributions to advance healthcare."
About Andrew von Eschenbach
Dr. von Eschenbach serves on the Board of Directors of the Reagan-Udall Foundation for the Food and Drug Administration. He is currently President of Samaritan Health Initiatives, a private consulting firm that focuses on improving the ecosystem for the discovery, development, and delivery of innovative 21st century solutions to eliminate disease and restore health, and an Adjunct Professor at the University of Texas UT MD Anderson Cancer Center. In addition, Dr. von Eschenbach is a Senior Fellow and Board member of various research institutions, pharmaceutical and healthcare companies. From 2006 to 2009, Dr. von Eschenbach served as Commissioner of the U.S. Drug and Food Administration, after being appointed Acting Commissioner in 2005. Prior to that, he served as Director of the National Cancer Institute from 2002 to 2006, after spending 26 years at the University of Texas M.D. Anderson Cancer Center, including as Director, Genitourinary Cancer Center.
Dr. von Eschenbach received a B.S. in biology from St. Joseph's University and a MD from Georgetown University School of Medicine.
About Target RWE
Target RWE is a leading health evidence solutions company that generates innovative real-world evidence (RWE) and provides scientific intelligence tools and solutions for pharmaceutical, biotechnology, and other healthcare partners. Specifically designed to address the complexities of the natural history of disease, the drug development process and treatments in real-world settings, Target RWE builds regulatory-grade clinical data sets and applies state of the science epidemiologic methods to produce RWE about patients with specific conditions, symptoms, and therapies used in usual clinical practice.
Target RWE's regulatory-grade data sets and evidence, modern epidemiological methods, and sound scientific principles rendered as software can be utilized to better health outcomes, inform patient health guidelines, and improve overall quality of care. For more information, visit www.targetrwe.com.
984.234.0268 ext 205
12/15/2021Target RWE Dermatology Study Data Shared at 3rd Annual RAD Conference
11/30/2021Target RWE Appoints Derek Evans as President
11/03/2021Peer-Reviewed Target RWE Study Finds Wide Variance in Nonalcoholic Steatohepatitis (NASH) Pathology Reporting
10/11/2021Target RWE Inflammatory Bowel Disease Research Presented at UEG Week 2021
09/13/2021Update from Paris NASH 2021: New Target RWE Nonalcoholic Steatohepatitis (NASH) Data Presented at This Year’s Meeting